AR060306A1 - ANTIBODY COMBINATION THERAPY AGAINST CTLA4 - Google Patents

ANTIBODY COMBINATION THERAPY AGAINST CTLA4

Info

Publication number
AR060306A1
AR060306A1 ARP070101443A ARP070101443A AR060306A1 AR 060306 A1 AR060306 A1 AR 060306A1 AR P070101443 A ARP070101443 A AR P070101443A AR P070101443 A ARP070101443 A AR P070101443A AR 060306 A1 AR060306 A1 AR 060306A1
Authority
AR
Argentina
Prior art keywords
combination therapy
antibody combination
therapy against
ctla4
treatment
Prior art date
Application number
ARP070101443A
Other languages
Spanish (es)
Inventor
Jesus Gomez-Navarro
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR060306A1 publication Critical patent/AR060306A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Administracion de un anticuerpo anti-CTLA4, particularmente anticuerpos humanos contra CTLA4 humano, tales como los que tienen las secuencias de aminoácidos de los anticuerpos 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, CP-675.206 (11.2.1), e ipilimumab, en combinacion con un agente terapéutico para el tratamiento del cáncer. Un procedimiento que comprende administrar un anticuerpo anti-CTLA4, preferiblemente, CP-675.206, y un agente quimioterapéutico, preferiblemente, gemcitabina, para el tratamiento de cáncer pancreático, entre otras modalidades de tratamiento.Administration of an anti-CTLA4 antibody, particularly human antibodies against human CTLA4, such as those having the amino acid sequences of the antibodies 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3 , 6.1.1, 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, CP-675.206 (11.2.1), and ipilimumab, in combination with a therapeutic agent for the treatment of cancer. A method comprising administering an anti-CTLA4 antibody, preferably, CP-675.206, and a chemotherapeutic agent, preferably gemcitabine, for the treatment of pancreatic cancer, among other treatment modalities.

ARP070101443A 2006-04-05 2007-04-04 ANTIBODY COMBINATION THERAPY AGAINST CTLA4 AR060306A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78966206P 2006-04-05 2006-04-05

Publications (1)

Publication Number Publication Date
AR060306A1 true AR060306A1 (en) 2008-06-04

Family

ID=38459642

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101443A AR060306A1 (en) 2006-04-05 2007-04-04 ANTIBODY COMBINATION THERAPY AGAINST CTLA4

Country Status (6)

Country Link
EP (1) EP2007423A2 (en)
JP (1) JP2007277242A (en)
AR (1) AR060306A1 (en)
CA (1) CA2647282A1 (en)
TW (1) TW200808348A (en)
WO (1) WO2007113648A2 (en)

Families Citing this family (207)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI531652B (en) 2005-12-02 2016-05-01 美國紐約大學西奈山醫學院 Chimeric viruses presenting non-native surface proteins and uses thereof
BRPI0710645A2 (en) 2006-04-07 2012-03-20 The Procter & Gamble Company ANTIBODIES BINDING TO HUMAN PROTEIN TYROSINE PHOSPHATASE BETA (HPTPBETA) AND USES OF THE SAME
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
WO2009064738A2 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
UA104579C2 (en) 2007-12-10 2014-02-25 Байокрист Фармасьютикалз, Инк. Method of treating hematologic cancer using pnp inhibitors such as forodesine in combination with alkylating agents or anti-cd20 agents
CN101909693A (en) * 2008-01-08 2010-12-08 百时美施贵宝公司 Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
JP2011512332A (en) * 2008-02-11 2011-04-21 キュアー テック リミテッド Monoclonal antibodies for tumor therapy
JP2011515478A (en) * 2008-03-25 2011-05-19 シェーリング コーポレイション Methods for treating or preventing colorectal cancer
US20100041048A1 (en) * 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
WO2010018846A1 (en) * 2008-08-13 2010-02-18 協和発酵キリン株式会社 Drug containing antibody composition specifically binding to ganglioside gm2
WO2010042433A1 (en) 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
WO2010086964A1 (en) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 Combination therapy for treating cancer
SI2769737T1 (en) 2009-07-20 2017-06-30 Bristol-Myers Squibb Company Combination of an anti-CTLA4 antibody with etoposide for the synergistic treatment of proliferative diseases
AU2015203324B2 (en) * 2009-07-20 2016-07-28 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
CN104826106B (en) * 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 Combination immunotherapy for treating cancer
CA2777226A1 (en) * 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
US8834423B2 (en) 2009-10-23 2014-09-16 University of Pittsburgh—of the Commonwealth System of Higher Education Dissolvable microneedle arrays for transdermal delivery to human skin
BR112012007523A2 (en) 2009-10-23 2017-06-20 Amgen British Columbia anti-gcc antibody molecules and related compositions and methods
BR112012029066A2 (en) * 2010-05-14 2020-09-01 The General Hospital Corporation compositions and processes for the identification of tumor-specific neoantigens.
WO2011146382A1 (en) * 2010-05-17 2011-11-24 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
JP5904552B2 (en) * 2010-05-28 2016-04-13 国立研究開発法人国立がん研究センター Pancreatic cancer treatment
CA2806252C (en) 2010-07-29 2019-05-14 Xencor, Inc. Antibodies with modified isoelectric points
CN103476943A (en) 2011-03-10 2013-12-25 普罗维克图斯药品公司 Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
US20120321637A1 (en) * 2011-06-20 2012-12-20 The Board Of Regents Of The University Of Texas System Combination cancer therapy with herv inhibition
WO2013056240A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
EP4112112A1 (en) * 2012-05-01 2023-01-04 University of Pittsburgh - Of the Commonwealth System of Higher Education Tip-loaded microneedle arrays for transdermal insertion
PE20142406A1 (en) 2012-05-04 2015-01-23 Pfizer ANTIGENS ASSOCIATED WITH PROSTATE AND VACCINE-BASED IMMUNOTHERAPY REGIMES
US10034939B2 (en) * 2012-10-26 2018-07-31 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
EP2945969A1 (en) 2013-01-15 2015-11-25 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JP6596411B2 (en) 2013-03-14 2019-10-23 アイカーン スクール オブ メディシン アット マウント サイナイ Newcastle disease virus and use thereof
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015058048A1 (en) * 2013-10-18 2015-04-23 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
WO2015134605A1 (en) 2014-03-05 2015-09-11 Bristol-Myers Squibb Company Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CA2943640A1 (en) * 2014-03-26 2015-10-01 Tocagen Inc. A retroviral vector having immune-stimulating activity
CN111410691B (en) 2014-03-28 2024-02-13 Xencor公司 Bispecific antibodies that bind to CD38 and CD3
WO2015153820A1 (en) * 2014-04-02 2015-10-08 Felder Mitchell S Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer
DK3142751T3 (en) * 2014-05-13 2019-10-14 Medimmune Ltd Anti-B7-H1 and anti-CTLA-4 antibodies for the treatment of non-small cell lung cancer
CN106714839A (en) 2014-05-15 2017-05-24 百时美施贵宝公司 Treatment of lung cancer using a combination of an anti-PD-1 antibody and another anti-cancer agent
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CN107072984B (en) * 2014-07-15 2021-10-01 约翰·霍普金斯大学 Bone marrow derived suppressor cell suppression and immune checkpoint blockade
SG10201900886RA (en) 2014-08-01 2019-03-28 3M Innovative Properties Co Methods and therapeutic combinations for treating tumors
CN105296433B (en) 2014-08-01 2018-02-09 中山康方生物医药有限公司 A kind of CTLA4 antibody, its medical composition and its use
KR101940430B1 (en) * 2014-08-07 2019-01-18 가꼬우호우징 효고 이카다이가쿠 Therapeutic agent for cancer which comprises combination of il-18 and molecule-targeting antibody
US20170281624A1 (en) 2014-09-13 2017-10-05 Novartis Ag Combination therapies of alk inhibitors
EA201790737A1 (en) * 2014-10-03 2017-08-31 Новартис Аг COMBINED THERAPY
EP4245376A3 (en) 2014-10-14 2023-12-13 Novartis AG Antibody molecules to pd-l1 and uses thereof
EA036498B1 (en) 2014-10-29 2020-11-17 Сиэтл Дженетикс, Инк. Dosage and administration of non-fucosylated anti-cd40 antibodies
US11236139B2 (en) 2014-11-05 2022-02-01 The Regents Of The University Of California Combination immunotherapy
WO2016075174A1 (en) * 2014-11-11 2016-05-19 Medimmune Limited Therapeutic combinations for treating neoplasia
LT3223845T (en) 2014-11-26 2021-08-25 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016086196A2 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) * 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3265090A4 (en) 2015-03-06 2018-08-01 Beyondspring Pharmaceuticals Inc. Method of treating cancer associated with a ras mutation
CA2978318A1 (en) * 2015-03-11 2016-09-15 Providence Health & Services-Oregon Compositions and methods for enhancing the efficacy of cancer therapy
WO2016149673A1 (en) 2015-03-18 2016-09-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Bioactive components conjugated to substrates of microneedle arrays
CN114907481A (en) 2015-03-23 2022-08-16 震动疗法股份有限公司 Antibodies to ICOS
ES2813580T3 (en) 2015-04-17 2021-03-24 Bristol Myers Squibb Co Compositions comprising a combination of ipilimumab and nivolumab
EP3288980B1 (en) 2015-04-28 2021-03-10 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
WO2016176503A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
AU2016263808B2 (en) 2015-05-21 2019-01-03 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
GB201509338D0 (en) * 2015-05-29 2015-07-15 Bergenbio As Combination therapy
BR112017025564B8 (en) 2015-05-29 2022-01-04 Agenus Inc Anti-ctla-4 antibodies and methods of using them
US11078278B2 (en) 2015-05-29 2021-08-03 Bristol-Myers Squibb Company Treatment of renal cell carcinoma
CA2987115C (en) * 2015-06-01 2024-02-20 Peter C. Brooks Enhancing the therapeutic activity of an immune checkpoint inhibitor
NZ738406A (en) * 2015-06-11 2023-04-28 Bionomics Ltd Pharmaceutical combination of a tubulin polymerization inhibitor with an inhibitor of pd-l1, pd-1, or ctla-4 and uses and compositions thereof
EP3316874A4 (en) * 2015-06-30 2019-03-06 The Trustees Of The University Of Pennsylvania Resiquimod topical and injectable compositions for the treatment of neoplastic skin conditions
EP3334726B1 (en) 2015-07-13 2022-03-16 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
SI3322731T1 (en) 2015-07-14 2021-03-31 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1)
WO2017066768A1 (en) 2015-10-16 2017-04-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Mullti-component biio-active drug delivery and controlled release to the skin by microneedle array devices
KR20180066236A (en) 2015-10-22 2018-06-18 조운스 테라퓨틱스, 인크. Gene traits for measuring ICOS expression
WO2017087870A1 (en) 2015-11-18 2017-05-26 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
SI3394093T1 (en) 2015-12-23 2022-05-31 Modernatx, Inc. Methods of using ox40 ligand encoding polynucleotides
WO2017119484A1 (en) 2016-01-08 2017-07-13 大鵬薬品工業株式会社 Anti-tumor agent containing immunomodulator, and anti-tumor effect enhancer
US20190241658A1 (en) 2016-01-10 2019-08-08 Modernatx, Inc. Therapeutic mRNAs encoding anti CTLA-4 antibodies
MY192703A (en) 2016-02-08 2022-09-02 Beyondspring Pharmaceuticals Inc Compositions containing tucaresol or its analogs
US10906977B2 (en) 2016-02-18 2021-02-02 Maine Medical Center Research Institute Enhancing the therapeutic activity of immune checkpoint inhibitor
WO2017155846A1 (en) * 2016-03-06 2017-09-14 The University Of Pennsylvania Immuno-gene combination therapy
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
EP3448428A4 (en) * 2016-04-25 2019-11-27 Medimmune, LLC Compositions comprising coformulation of anti-pd-l1 and anti-ctla-4 antibodies
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
JP7194594B2 (en) 2016-05-18 2022-12-22 モデルナティエックス インコーポレイテッド Combinations of mRNAs encoding immunomodulatory polypeptides and uses thereof
LT3458083T (en) 2016-05-18 2023-02-10 Modernatx, Inc. Polynucleotides encoding interleukin-12 (il12) and uses thereof
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
DK4019019T3 (en) 2016-05-20 2024-05-06 Biohaven Therapeutics Ltd USE OF RILUZOLE, RILUZOLE PRODUCTS, OR RILUZOLE ANALOGUES WITH IMMUNE THERAPIES FOR THE TREATMENT OF CANCER
PT3463457T (en) 2016-06-02 2023-09-07 Bristol Myers Squibb Co Pd-1 blockade with nivolumab in refractory hodgkin's lymphoma
US11419927B2 (en) * 2016-06-02 2022-08-23 Ultimovacs As Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
JP2019517498A (en) 2016-06-03 2019-06-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Anti-PD-1 antibody for use in a method of treating recurrent small cell lung cancer
WO2017210637A1 (en) 2016-06-03 2017-12-07 Bristol-Myers Squibb Company Use of anti-pd-1 antibody in the treatment of patients with colorectal cancer
MX2018015100A (en) 2016-06-06 2019-09-04 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia.
US10787518B2 (en) 2016-06-14 2020-09-29 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
KR20190020341A (en) 2016-06-28 2019-02-28 젠코어 인코포레이티드 Heterozygous antibodies that bind to somatostatin receptor 2
SG10201912556VA (en) 2016-07-20 2020-02-27 Aerpio Therapeutics Inc HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
NL2017270B1 (en) 2016-08-02 2018-02-09 Aduro Biotech Holdings Europe B V New anti-hCTLA-4 antibodies
KR20230044038A (en) 2016-08-09 2023-03-31 키맵 리미티드 Anti-icos antibodies
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
CN116617387A (en) * 2016-08-29 2023-08-22 迪赞纳生命科学公开有限公司 anti-CD 3 antibody formulations
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
EP3526259A4 (en) * 2016-10-13 2020-06-17 Dana-Farber Cancer Institute, Inc. Compositions and methods for predicting response and resistance to ctla4 blockade in melanoma using a gene expression signature
AU2017342560B2 (en) 2016-10-14 2022-03-17 Xencor, Inc. IL15/IL15Ralpha heterodimeric Fc-fusion proteins
US20190315865A1 (en) 2016-10-28 2019-10-17 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
JP2019534044A (en) * 2016-11-08 2019-11-28 クイル ピュージェット サウンド バイオセラピューティクス コーポレーション Anti-PD1 and anti-CTLA4 antibodies
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
KR20230037664A (en) 2016-12-07 2023-03-16 아게누스 인코포레이티드 Anti-ctla-4 antibodies and methods of use thereof
JP2020503363A (en) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Tubulin binding compounds and their therapeutic use
WO2018144764A1 (en) 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia
EP3601355A1 (en) 2017-03-31 2020-02-05 Bristol-Myers Squibb Company Methods of treating tumor
TWI788340B (en) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 Anti-icos agonist antibodies and uses thereof
JP7090347B2 (en) 2017-05-12 2022-06-24 ハープーン セラピューティクス，インク． Mesothelin-binding protein
JOP20190256A1 (en) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
JP7285220B2 (en) 2017-05-18 2023-06-01 モデルナティエックス インコーポレイテッド Lipid nanoparticles comprising linked interleukin-12 (IL12) polypeptide-encoding polynucleotides
EP4245375A3 (en) 2017-05-30 2023-12-06 Bristol-Myers Squibb Company Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
JP2020529832A (en) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド Targeted heterodimer Fc fusion protein containing IL-15 / IL-15Rα and antigen binding domain
EA202090739A1 (en) 2017-10-13 2020-09-07 Харпун Терапьютикс, Инк. PROTEINS BINDING ANTIGEN OF MATURING B-CELLS
KR20200064132A (en) 2017-10-15 2020-06-05 브리스톨-마이어스 스큅 컴퍼니 How to treat a tumor
KR20200085828A (en) 2017-11-08 2020-07-15 젠코어 인코포레이티드 Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
KR20200109339A (en) 2018-01-16 2020-09-22 브리스톨-마이어스 스큅 컴퍼니 How to treat cancer using antibodies to TIM3
CA3088542A1 (en) 2018-01-22 2019-07-25 Bristol-Myers Squibb Company Compositions and methods of treating cancer
KR20200112881A (en) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. Composition and method for reducing thrombocytopenia through administration of plinabulin
TW202003565A (en) 2018-03-23 2020-01-16 美商必治妥美雅史谷比公司 Antibodies against MICA and/or MICB and uses thereof
WO2019191676A1 (en) 2018-03-30 2019-10-03 Bristol-Myers Squibb Company Methods of treating tumor
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112437777A (en) 2018-04-18 2021-03-02 Xencor股份有限公司 TIM-3 targeting heterodimeric fusion proteins comprising an IL-15/IL-15RA Fc fusion protein and a TIM-3 antigen binding domain
US11524991B2 (en) 2018-04-18 2022-12-13 Xencor, Inc. PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof
WO2020014583A1 (en) 2018-07-13 2020-01-16 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a mehtod of treating a cancer or a solid tumor
CA3114038A1 (en) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
JP2022505647A (en) 2018-10-23 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー How to treat a tumor
EP3873940A4 (en) * 2018-10-31 2022-11-30 BioAtla, Inc. Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US20220001026A1 (en) 2018-11-08 2022-01-06 Modernatx, Inc. Use of mrna encoding ox40l to treat cancer in human patients
PE20211284A1 (en) 2018-11-16 2021-07-19 Bristol Myers Squibb Co ANTI-NKG2A ANTIBODIES AND USES OF THEM
EP3880231A1 (en) 2018-11-16 2021-09-22 NeoImmuneTech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
JP2022511437A (en) 2018-11-26 2022-01-31 デバイオファーム インターナショナル エス．エー． Combined treatment of HIV infection
SG11202106898VA (en) 2018-12-28 2021-07-29 Transgene Sa M2-defective poxvirus
CN114173875A (en) 2019-03-01 2022-03-11 Xencor股份有限公司 Heterodimeric antibodies that bind ENPP3 and CD3
KR20210146349A (en) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 how to treat a tumor
KR20210146348A (en) 2019-03-28 2021-12-03 브리스톨-마이어스 스큅 컴퍼니 how to treat a tumor
BR112021019405A2 (en) * 2019-04-01 2021-11-30 Cytodyn Inc Anti-ccr5 agents and treatment methods that block cancer metastasis or enhance DNA-damaging chemotherapy-induced cell death
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
KR20220016156A (en) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 Polyoncogene signatures for suitability for immuno-oncology therapy
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
US20220348653A1 (en) 2019-09-22 2022-11-03 Bristol-Myers Squibb Company Quantitative Spatial Profiling for LAG-3 Antagonist Therapy
WO2021062332A1 (en) * 2019-09-27 2021-04-01 Icahn School Of Medicine At Mount Sinai Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer
WO2021092220A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
WO2021092221A1 (en) 2019-11-06 2021-05-14 Bristol-Myers Squibb Company Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy
AU2020380384A1 (en) 2019-11-08 2022-05-26 Bristol-Myers Squibb Company LAG-3 antagonist therapy for melanoma
AU2020407130A1 (en) 2019-12-19 2022-06-16 Bristol-Myers Squibb Company Combinations of DGK inhibitors and checkpoint antagonists
WO2021146323A1 (en) * 2020-01-13 2021-07-22 Cytodyn Inc. Ccr5 binding agent for treatment of ccr5 positive metastatic breast cancer
EP4100426A1 (en) 2020-02-06 2022-12-14 Bristol-Myers Squibb Company Il-10 and uses thereof
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
US20230233474A1 (en) 2020-05-28 2023-07-27 Modernatx, Inc. Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
KR102607909B1 (en) 2020-08-19 2023-12-01 젠코어 인코포레이티드 Anti-CD28 composition
KR20230058442A (en) 2020-08-28 2023-05-03 브리스톨-마이어스 스큅 컴퍼니 LAG-3 antagonist therapy for hepatocellular carcinoma
WO2022047412A1 (en) 2020-08-31 2022-03-03 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
JP2023548051A (en) 2020-10-23 2023-11-15 ブリストル－マイヤーズ スクイブ カンパニー LAG-3 antagonist therapy for lung cancer
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
MX2023007650A (en) 2020-12-28 2023-09-11 Bristol Myers Squibb Co Subcutaneous administration of pd1/pd-l1 antibodies.
JP2024503265A (en) 2020-12-28 2024-01-25 ブリストル－マイヤーズ スクイブ カンパニー Antibody compositions and methods of use thereof
AU2022232375A1 (en) 2021-03-09 2023-09-21 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
IL309227A (en) 2021-10-29 2024-02-01 Bristol Myers Squibb Co Lag-3 antagonist therapy for hematological cancer
KR20240130705A (en) 2021-12-30 2024-08-29 네오이뮨텍, 인코퍼레이티드 Method for treating tumors with a combination of IL-7 protein and VEGF antagonist
IL314050A (en) 2022-01-26 2024-09-01 Bristol Myers Squibb Co Combination therapy for hepatocellular carcinoma
WO2023154796A2 (en) * 2022-02-09 2023-08-17 Dragonfly Therapeutics, Inc. Pharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16
AU2023226078A1 (en) 2022-02-25 2024-08-22 Bristol-Myers Squibb Company Combination therapy for colorectal carcinoma.
WO2023168404A1 (en) 2022-03-04 2023-09-07 Bristol-Myers Squibb Company Methods of treating a tumor
WO2023170606A1 (en) 2022-03-08 2023-09-14 Alentis Therapeutics Ag Use of anti-claudin-1 antibodies to increase t cell availability
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023196987A1 (en) 2022-04-07 2023-10-12 Bristol-Myers Squibb Company Methods of treating tumor
WO2023196988A1 (en) 2022-04-07 2023-10-12 Modernatx, Inc. Methods of use of mrnas encoding il-12
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024003353A1 (en) 2022-07-01 2024-01-04 Transgene Fusion protein comprising a surfactant-protein-d and a member of the tnfsf
CN115806629A (en) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 Autocrine IL-15 and anti-CTLA4 combined fusion protein and application thereof
WO2024040175A1 (en) 2022-08-18 2024-02-22 Pulmatrix Operating Company, Inc. Methods for treating cancer using inhaled angiogenesis inhibitor
US20240173401A1 (en) * 2022-09-21 2024-05-30 Wisconsin Alumni Research Foundation Compositions and Methods to Enhance Therapeutic Efficacy of Cancer Therapies
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
WO2024137776A1 (en) 2022-12-21 2024-06-27 Bristol-Myers Squibb Company Combination therapy for lung cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
JP2008518902A (en) * 2004-11-04 2008-06-05 ファイザー・プロダクツ・インク Combination therapy of CTLA4 antibody and aromatase inhibitor for breast cancer
EP1863532A1 (en) * 2005-03-23 2007-12-12 Pfizer Products Incorporated Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
NZ565311A (en) * 2005-07-07 2009-10-30 Pfizer Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment

Also Published As

Publication number Publication date
WO2007113648A3 (en) 2008-03-20
WO2007113648A2 (en) 2007-10-11
TW200808348A (en) 2008-02-16
EP2007423A2 (en) 2008-12-31
JP2007277242A (en) 2007-10-25
CA2647282A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
AR060306A1 (en) ANTIBODY COMBINATION THERAPY AGAINST CTLA4
AR047841A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNE-INFLAMMATORY DISORDERS
AR053651A1 (en) COMBINED TREATMENT OF ANTIBODY ANTICTLA4 R AROMATASE INHIBITOR FOR BREAST CANCER
DOP2017000271A (en) PATIENT CONDITIONING METHODS FOR T-LYMPHOCYT TREATMENT
DOP2017000177A (en) NEW ANTI-CD38 ANTIBODIES FOR CANCER TREATMENT
AR049985A1 (en) COMBINATION TREATMENT FOR NON-HEMATOLOGICAL MALIGNAL DISEASES
CR8380A (en) METHODS FOR PREPARING AND USING NEW DEVELOPMENTS OF MOTHER CELLS AND THEIR ASSEMBLIES
CO6361942A2 (en) COMBINATION THERAPY WITH PEPTIDIC EPOXYCETONES
AR105712A1 (en) QUICK ACTION INSULIN COMPOSITIONS
UY32177A (en) TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO
WO2017177179A9 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
AR074203A1 (en) ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER. KIT USE.
MX2017014338A (en) Targeted selection of patients for treatment with cortistatin derivatives.
PA8588601A1 (en) COMBINED ADMINISTRATION OF AN INDOLINONE WITH A CHEMOTHERAPEUTIC AGENT FOR THE TREATMENT OF CELL PROLIFERATION DISEASES
EA200801853A1 (en) EFFECTIVE PEPTIDES IN THE TREATMENT OF TUMORS AND OTHER DISEASES THAT REQUIRE REMOVAL OR DESTRUCTION OF CELLS
UY32739A (en) COMBINATIONS OF CHEMOTHERAPIC AGENTS AND ANTAGONISTS DLL4 AND ITS USES IN CANCER THERAPY
AR067903A1 (en) METHOD TO TREAT STRESSED DEPRESSION
BR112019007210A2 (en) Methods and Compositions for the Treatment of Fabry Disease
JO3709B1 (en) A pharmaceutical composition or kit for use in treating cancer in a mammal comprising asparaginase and methioninase
UY30158A1 (en) USE OF BENZO-HETEROARIL SULFAMIDA DERIVATIVES FOR PAIN TREATMENT
MX2020004837A (en) Adenosine pathway inhibitors for cancer treatment.
UY29441A1 (en) OBLEA CONTAINING STEROID HORMONES
MX2019012660A (en) Method for treating cancer using a bcl-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic.
PA8574001A1 (en) USE OF DOCETAXEL IN COMBINATION WITH DOXORRUBICINE AND CYCLOFOSPHAMIDE AS AN ADJUSING THERAPY
BR112015010039A2 (en) treatment of cancer with pomalidomide in an individual with renal dysfunction

Legal Events

Date Code Title Description
FB Suspension of granting procedure